Effect of Xuebijing injection (血必净注射液) on systemic lupus erythematosus in mice

Yan-bo Wang; Qiang Wang; Yong-ming Yao; Zhi-yong Sheng; Yu-feng Liu

doi:10.1007/s11655-013-1561-0

Your Location：

Home >

Browse articles >

Effect of Xuebijing injection (血必净注射液) on systemic lupus erythematosus in mice

OriginalPaper | Updated：2021-08-27

- Effect of Xuebijing injection (血必净注射液) on systemic lupus erythematosus in mice
- Effect of Xuebijing injection (血必净注射液) on systemic lupus erythematosus in mice
- 中国结合医学杂志（英文版） 2013年19卷第9期页码：675-682
- Affiliations：
  
  1. Department of Dermatology, Xijing Hospital, Fourth Military Medical University,Xi’an,China
  2. Chinese Center for Disease Control and Prevention,Beijing,China
  3. Burns Institute, First Hospital Affiliated to the Chinese PLA General Hospital,Beijing,China
- Author bio：
- Funds：
  
  Supported by Grants from the National Natural Science Foundation (No. 81130035, 81071545, and 30971192), and the National Basic Research Program of China (No. 2012CB518102)
- DOI：10.1007/s11655-013-1561-0
  中图分类号：
- 纸质出版日期：2013，
  
  网络出版日期：2013-8-24，
Scan for full text
Wang, Yb., Wang, Q., Yao, Ym. et al. Effect of Xuebijing injection (血必净注射液) on systemic lupus erythematosus in mice., Chin. J. Integr. Med. 19, 675–682 (2013). https://doi.org/10.1007/s11655-013-1561-0

Yan-bo Wang, Qiang Wang, Yong-ming Yao, et al. Effect of Xuebijing injection (血必净注射液) on systemic lupus erythematosus in mice[J]. Chinese Journal of Integrative Medicine, 2013,19(9):675-682.
Wang, Yb., Wang, Q., Yao, Ym. et al. Effect of Xuebijing injection (血必净注射液) on systemic lupus erythematosus in mice., Chin. J. Integr. Med. 19, 675–682 (2013). https://doi.org/10.1007/s11655-013-1561-0 DOI：

Yan-bo Wang, Qiang Wang, Yong-ming Yao, et al. Effect of Xuebijing injection (血必净注射液) on systemic lupus erythematosus in mice[J]. Chinese Journal of Integrative Medicine, 2013,19(9):675-682. DOI： 10.1007/s11655-013-1561-0.

摘要

To observe the effects of Xuebijing Injection (血必净注射液) on dendritic cells (DCs) and T lymphocytes

and the potential mechanisms of its therapeutic effect on systemic lupus erythematosus (SLE). A widely used mouse model

SLE-prone BLLF1 mice aged 8–10 weeks

was employed. Mice were randomly divided into 4 groups: a normal group

a model group and two treatment groups treated with Xuebijing Injection with a dose of 6.4 mL/kg via intraperitoneal administration for SLE-prone BLLF1 mice aged 8 weeks (treatment A group) and 10 weeks (treatment B group). Renal tissue sections were stained with Masson’s trichrome and periodic acid-silver methenamine. Histopathological changes in the kidney were evaluated by a light microscopy. The capacity of the DCs isolated from the spleen to stimulate the T cell proliferation in response to concanavalin A (Con A) was determined. Compared with the model group

levels of anti-dsDNA antibodies in the two treatment groups decreased remarkablely (P<0.01

P<0.05)

and levels of serum creatinine and blood urea nitrogen increased (P<0.01

P<0.05). Pathological changes were found in the kidney in the model group. Histopathological abnormalities were alleviated in the two treatment groups. Treatment with Xuebijing injection also significantly upregulated the expression of CD80

CD86 and major histocompatibility class II by DCs compared with the model group (P<0.05). When splenic T lymphocytes from BLLF1 mice were co-cultured with DCs at ratios of 1:100

1:150 and 1:200 for 3 and 5 days

the proliferation of T lymphocytes was suppressed compared with the normal group (P<0.05)

but this was restored by Xuebijing Injection under the same conditions. In the model group

levels of tumor necrosis factor (TNF)-α in supernatants were significantly elevated compared with the normal group (P<0.01)

interleukin-2 levels decreased (P<0.05)

while these changes were significantly alleviated in the Xuebijing treatment groups. Xuebijing Injection alleviated renal injury in SLE-prone BLLF-1 mice. The mechanism might be through influencing T cell polarization mediated by DCs

and Xuebijing Injection might be a potential drug that suppresses immune dysfunction in patients with SLE.

Abstract

To observe the effects of Xuebijing Injection (血必净注射液) on dendritic cells (DCs) and T lymphocytes

and the potential mechanisms of its therapeutic effect on systemic lupus erythematosus (SLE). A widely used mouse model

SLE-prone BLLF1 mice aged 8–10 weeks

was employed. Mice were randomly divided into 4 groups: a normal group

levels of anti-dsDNA antibodies in the two treatment groups decreased remarkablely (P<0.01

P<0.05)

and levels of serum creatinine and blood urea nitrogen increased (P<0.01

CD86 and major histocompatibility class II by DCs compared with the model group (P<0.05). When splenic T lymphocytes from BLLF1 mice were co-cultured with DCs at ratios of 1:100

1:150 and 1:200 for 3 and 5 days

the proliferation of T lymphocytes was suppressed compared with the normal group (P<0.05)

but this was restored by Xuebijing Injection under the same conditions. In the model group

levels of tumor necrosis factor (TNF)-α in supernatants were significantly elevated compared with the normal group (P<0.01)

interleukin-2 levels decreased (P<0.05)

and Xuebijing Injection might be a potential drug that suppresses immune dysfunction in patients with SLE.

关键词

Xuebijing Injectionsystemic lupus erythematosusLupus Nephritisdendritic cellT lymphocytecytokineproliferative responsemice

Keywords

Xuebijing Injectionsystemic lupus erythematosusLupus Nephritisdendritic cellT lymphocytecytokineproliferative responsemice

references

Zhang LT, Yao YM, Dong N, Dong YQ, Yu Y, Sheng ZY. Relationship between high-mobility group box 1 protein release and T-cell suppression in rats after thermal injury. Shock 2008;30:449–455.

Zhu XM, Yao YM, Liang HP, Liu F, Dong N, Yu Y, et al. Effect of high mobility group box-1 protein on apoptosis of peritoneal macrophages. Arch Biochem Biophys 2009;492:54–61.

Berkun Y, Verboverski I, Ben-Ami A, Paran D. Altered dentritic cells with tolerizing phenotype in patients with systemic-lupus erythematosus. Eur J Immunol 2008;38:2896–2904.

Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation: friend or foe? Immunity 2001;14:357–368.

Banchereau J, Briere F, Caux C. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767–811.

Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271–296.

Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245–3287.

Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255–258.

Steinman RM. Dendritic cells: understanding immunogenicity. Eur J Immunol 2007;37:S53–S60.

Steinman RM. Lasker basic medical research award. dendritic cells: versatile controllers of the immune system. Nat Med 2007;13:1155–1159.

Pichlmair A, Reis E, Sousa C. Innate recognition of viruses. Immunity 2007;27:370–383.

Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685–711.

Dumitriu IE, Baruah P, Bianchi ME, Manfredi AA, Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol 2005;35:2184–2190.

Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004;173:307–313.

Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005;174:7506–7515.

Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007;1:59–66.

Flohé SB, Agrawal H, Schmitz D, Gertz M, Flohé S, Schade FU. Dendritic cells during polymicrobial sepsis rapidly mature but fail to initiate a protective Th1-type immune response. J Leukoc Biol 2006;79:473–481.

Yao YM, Chai YK, Lin HY, eds. Sepsis theory and practice. Beijing: Science Press; 2005:1112–1152.

Wan JM, Sit WH, Lee CL, Fu KH, Chan DK. Protection of lethal toxicity of endotoxin by Salvia miltiorrhiza Bunge is via reduction in tumor necrosis factor alpha release and liver injury. Int Immunopharmacol 2006;6:750–758.

Wang H, Li W, Li J, Rendon-Mitchell B, Ochani M, Yang L, et al. The aqueous extract of a popular berbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J Nutr 2006;136:360–365.

Lv GF, Zheng J, Zhou H, Zheng YM, Wang LX, Wei G, et al. The screening and isolation of an effective anti-endotoxin monomer from Radix Paeoniae Rubra using affinity biosensor technology. Int Immunopharmaool 2005;5:1007–1017.

FULL TEXT LINK

More>

浏览量

607

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Effects of Ginkgo leaf extract on function of dendritic cells and Th1/Th2 cytokines in patients with unstable angina pectoris

Treatment of fibrillary glomerulonephritis by corticosteroids and tripterygium glycoside tablets: A case report

Effects of herbal compound 861 on collagen synthesis and degradation in rat mesangial cells exposed to high glucose

Anti-inflammatory effect of Qingwen Baidu Decoction (清瘟败毒饮) in sepsis rats

The efficacy and safety of Jitongning Capsule (脊痛宁胶囊) in patients with ankylosing spondylitis